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SUMMARY
The quest for new antiparasitic alternatives has led researchers to base their studies on insights into biology, host-parasite 
interactions and pathogenesis. In this context, proteases and their inhibitors are focused, respectively, as druggable targets and new 
therapy alternatives. Herein, we proposed to evaluate the in vitro effect of the cysteine protease inhibitor E-64 on Giardia trophozoites 
growth, adherence and viability. Trophozoites (105) were exposed to E-64 at different final concentrations, for 24, 48 and 72 h at 37 
°C. In the growth and adherence assays, the number of trophozoites was estimated microscopically in a haemocytometer, whereas 
cell viability was evaluated by a dye-reduction assay using MTT. The E-64 inhibitor showed effect on growth, adherence and viability 
of trophozoites, however, its better performance was detected in the 100 µM-treated cultures. Although metronidazole was more 
effective, the E-64 was shown to be able to inhibit growth, adherence and viability rates by ≥ 50%. These results reveal that E-64 can 
interfere in some crucial processes to the parasite survival and they open perspectives for future investigations in order to confirm the 
real antigiardial potential of the protease inhibitors.
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INTRODUCTION
Giardia duodenalis (syn. Giardia lamblia, Giardia intestinalis), a 
worldwide zoonotic intestinal protozoan, is one of the major causes of 
non-viral diarrheal disease in humans. Despite giardiasis has a global 
distribution, higher infection rates (20-60%) have been reported for 
developing countries, mainly among socially and economically deprived 
populations22. Since in developed areas, infections rates are lower and 
G. duodenalis is often involved in numerous outbreaks that have been 
attributed to an inappropriate water treatment1. Considering the infection 
impact on health and on socio-economic improvements of developing 
nation’s population, Giardia was recently included in the WHO Neglected 
Diseases Initiative, a group including pathogens that have a common link 
with poverty20. In these areas, giardiasis is a common cause of diarrhea in 
nursery and school children22, especially in undernourished individuals, 
which in turn, gives rise to nutritional deficiencies leading to growth 
failure and cognitive impairment20.
So far, drug intervention has been recommended as a preventive 
strategy to limit and reduce the transmission of giardiasis. Currently, 
some therapeutic measures have been available in clinical practice for 
the treatment of giardiasis, highlighting acridine, 5-nitroimidazole, 
5-nitrofurans, 5-nitrothiazoles and benzimidazole derivates27. For 
decades, the most prescribed antigiardial drug is the metronidazole, a 
5-nitroimidazole compound that has a recognized antigiardial activity 
with cure rates ranging from 80 to 95%21. Despite its efficiency, treatment 
shows undesirable side effects, failures are common and evidences 
suggest the emergence of drug resistance2,9,14. Therefore, there is an 
increasing interest for new antigiardial agents that can be effective 
against the parasite, less harmful for the host and may provide options 
for refractory cases, especially for children, who may require treatment 
often because of reinfections.
Nowadays, the quest for new antiparasitic alternatives has led 
researchers to base their studies on insights into biology, host-
parasite interactions and pathogenesis. In light of this, advances in 
the understanding of the biochemistry and molecular biology of 
parasites have led to a better understanding of molecules which play 
a role in biological, metabolic and physiological processes. Among 
these molecules, the proteolytic enzymes or proteases have excited 
the researcher’s interest, once they have been identified as important 
virulent factors as well as potential chemotherapeutic targets in parasites. 
Considering that proteolytic activity is naturally regulated by specific 
inhibitors, the selective inhibition of crucial proteases can be a promising 
strategy to develop new antiparasitic therapies19. In this context, it is 
important to emphasize that proteases have been validated as druggable 
targets as evidenced by the use of protease inhibitors as effective therapy 
for hypertension, diabetes, osteoporosis, certain cancers and AIDS17,28. 
In relation to parasites, several protease targets have been validated by 
genetic or chemical knockout in protozoan parasites, and many other 
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enzymes appear promising as targets but they require more investigations 
for validation, or to identify viable drug leads. So, interesting results 
have been reported in studies with parasitic infections such as malaria, 
leishmaniasis and Chagas disease and they have provided important 
evidences that these substances selectively inhibit parasite proteases 
without affecting host homologues17.
With respect to Giardia, notwithstanding recent studies have shed 
light on trophozoites proteases and their involvement in metabolism and 
physiologic processes4,5,12,23 relatively little is known about the effect 
of protease inhibitors on vital processes of this parasite. To date, as far 
as we know, there are few studies that have evaluated the in vitro and 
in vivo performance of protease inhibitors on multiplication8,11 and on 
encystation/excystation7,23,24 of the parasite. Thus, considering the aspects 
above, here we report the in vitro effects of E-64, a specific cysteine 
protease inhibitor, on axenic trophozoites growth and adherence abilities, 
and viability. The results assembled here may open perspectives to pursue 
the development of further investigations in order to assess protease 
inhibitors as potential antigiardial agents.
MATERIALS AND METHODS
Parasite and cultivation conditions: G. duodenalis axenic 
trophozoites, BTU-11 strain, were axenically cultivated in filter-sterilized 
TYI-S-33 (Tryptcase, yeast extract, iron serum) medium, modified by 
KEISTER13 in 5 mL Vacutainer® tubes at 37 ºC. The strain isolated in 
Brazil at the Giardiasis Laboratory (IB/UNESP) in Botucatu, São Paulo 
was established from cysts of a symptomatic patient presenting diarrhea, 
flatulence, abdominal cramps and resistance to conventional therapy. 
Trophozoites harvested in log-phase growth 72 h postinoculation, after 
chilling in bath ice for 10 min, were collected by centrifugation at 250×g 
for 15 min at 4 °C. Pooled cells were resuspended in sterile phosphate-
buffered saline (PBS; pH 7.2) and the total number of trophozoites was 
counted microscopically in a haemocytometer (Neubauer cell-counter 
chamber) and adjusted to an inoculum of 105 parasites.
Preparation of inhibitor: E-64 [(L-trans-epoxysuccinyl-L-
leucylamido-(4-guanidino)-butane], a commercially available cysteine 
protease inhibitor was purchased from Sigma. The inhibitor was prepared 
at one mM in aqueous solution and stored at -20 ºC, until required. The 
inhibitor stock solution was diluted in sterile phosphate buffered saline 
(pH 7.2) at final concentrations of 10, 50 and 100 µM and sterilized in 
0.22 µm filter. The assayed concentrations were established according 
to inhibitor effective concentration3.
Growth inhibition assay: Firstly, an inoculum of 105 trophozoites 
were incubated in TYI-S-33 medium (4.5 mL/tube) containing the 
inhibitor at different concentrations (10, 50 and 100 µM) for 24, 48 
and 72 h at 37 ºC. After incubation, the tubes were cooled for 10 min, 
centrifuged at 250xg (10 min, 4 ºC) and the population density of cultures 
were estimated by counting in a haemocytometer. As controls, cultures 
containing only the parasites and cultures treated with metronidazole at 
40 µg/mL15 were included in all the assays and submitted to the same 
experimental conditions. For each E-64 concentration assessed, three 
tubes were screened and the protease inhibitor activity on the parasite 
growth was evaluated comparing the number of organisms in inhibitor-
treated cultures with their number in controls. The results were expressed 
as the trophozoites number and growth inhibition percentage.
Adherence assay: The E-64 effect on adherence of Giardia 
trophozoites was analyzed as previously described by EDLIND et 
al.10, with slight modifications. An inoculum of 105 organisms was 
incubated in TYI-S-33 medium for four hours at 37 ºC. The medium 
with unattached cells was replaced with one supplemented with E-64 at 
10, 50 and 100 µM. After incubation for 24 and 48 h at 37 ºC, adherent 
cells were dislodged by a 10 min on ice, centrifuged at 250xg and the 
number of attached cells was determined using a haemocytometer. 
Control assays were performed under similar experimental conditions 
with cultures in the absence of E-64 and cultures treated with 
metronidazole at 40 µg/mL15. For each inhibitor concentration, three 
tubes were assayed and the effect on adhesion capacity was evaluated 
comparing the number of organisms in E-64-treated cultures with their 
number in control cultures. The results were expressed as number of 
attached cells (percentage of control).
Cell viability assay: The effect of E-64 on trophozoites viability 
was evaluated by the quantitative colorimetric MTT-tetrazolium salt 
[3-(4,5-dimethilthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] 
technique, as previously described by PONCE-MACOTELA et al.18. 
Briefly, trophozoites (105) exposed to each E-64 concentration for 48 
and 72 h were transferred to 1.5 Eppendorf® tubes, washed with PBS 
(pH7.4) and incubated for 60 min at 37 ºC in a solution containing 40 
µL of MTT (5 mg/mL; Sigma) and 20 µL of the catalyst phenazine-
methosulfate (PMS 2.5 mg/mL; Sigma). Then, the cells were pelleted 
by centrifugation and the purple product obtained by the conversion 
of MTT to the formazan was resuspended in isopropanol/hydrochloric 
acid. The assay was performed in triplicate and aliquots of 150 µL were 
collected and the optical densities of each sample were measured at 540 
nm. The parasite viability was calculated regarding the untreated cultures 
(100% viability).
Statistical analysis: To evaluate E-64 effect on the growth, adherence 
and viability of Giardia trophozoites, a factorial design layout was 
employed for counting data following multiple comparisons. Data 
were submitted to analyze the variance (ANOVA) and the means were 
compared by Tukey’s test. All analyses were conducted in SAS 9.2 for 
Windows (SAS Institute Inc., Cary, NC) and p-values less than 0.05 
were deemed statistically significant. The inhibitory concentrations 
at 50% (IC50) were calculated from dose-response curves by linear 
regression analysis.
RESULTS AND DISCUSSION
As many efforts have been made to search new alternatives for 
Giardia infection treatment, the assessment of a drug potential requires 
suitable models that allow identifying the biological processes on which 
they can interfere. For this purpose, assays for in vitro screening are a 
preliminary step and advances in trophozoites axenic cultivation have 
allowed the investigation of antigiardial activity of a range of compounds, 
especially, in relation to their ability to exert effect on trophozoites 
growth, adherence and viability. The present study led to some interesting 
findings concerning the in vitro activity of the cysteine protease inhibitor 
E-64 on axenic trophozoites.
As shown in Figure 1, E-64 exerted inhibitory activity on parasite 
multiplication in a dose dependent manner. Considering the assayed 
concentrations of 10, 50 and 100 µM, growth inhibition was observed in 
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cultures exposed to the highest of them, in which the number of parasites 
recovered was significantly lower than that obtained in untreated cultures 
(p < 0.05). The inhibitory concentrations at 50% (IC50) were 144.29 
µM for 24 h, 53.72 µM for 48 h and 27.02 µM for 72 h. At both 48 and 
72 h, growth reduction by ≥ 50% and ≥ 70% were observed in cultures 
treated with 50 and 100 µM, respectively (p < 0.05). A significant level 
of inhibition (~80%) was detected in 72 h cultures treated with the 
100 µM, but the reduction rate was still lower than that obtained in 
metronidazole-treated cultures. In adherence assays (Fig. 2), only the 
concentrations of 50 and 100 µM were able to promote detachment of 
trophozoites. The IC50 values after 24 and 48 h were 128.65 µM and 
33.80 µM respectively. The greater activity was induced by the inhibitor 
at 100 µM after 48 h (p < 0.05) when only 10% of trophozoites remained 
attached. Despite E-64 markedly diminished parasite adherence at 100 
µM, the rates of metronidazole inhibition were higher. In both growth 
and adherence assays, E-64 exhibited a dose-response effect, however 
by light microscope observations, this activity was not accompanied 
by marked changes in trophozoites morphology as body swollen and 
reduction of flagellar beating frequency.
As in the growth and adherence assays, E-64 at 100 µM showed a 
very significant reduction of viability rate in comparison to non-treated 
cultures after 48 h (Fig. 3) (p < 0.05). The highest rates were detected 
after 48 h, when the inhibitor at 50 and 100 µM was able to kill 80% and 
93% of the trophozoites, respectively (p < 0.05). However, this effect 
was lower than that obtained by exposure to metronidazole (p < 0.05).
So far, the most widely used drug against Giardia infection is the 
metronidazole, a 5’-nitroimidazole derivate, although there are some 
problems related to resistance and toxicity. Once many antiparasitic 
drugs currently in use show the same disadvantages, recently, 
investigations have identified promising antiparasitic drug candidates 
as well as potential targets in parasites. In this context, proteases and 
their inhibitors are focused, respectively, as druggable targets and new 
therapy alternatives.
In the last years, several investigations have focused the potential 
of protease inhibitors in important parasitic infections such as malaria, 
Chagas’ disease, leishmaniasis and toxoplasmosis17 and they have revealed 
promising insights on the use of these substances, especially those against 
thiol or cysteine proteases. Regarding to Giardia, advances in the study of 
its proteases had become clear that this protozoan is actively proteolytic 
and contain multiple proteases, with the predominance of the cysteine 
peptidases that are responsible for the main proteolytic activity4,5,12,26.
In the present study, although metronidazole was very effective, 
the cysteine protease inhibitor E-64 was shown to be also efficient in 
affecting the parasite growth, adherence and viability. These biological 
parameters were inhibited by ≥ 50% at concentrations of 50 and 100 µM. 
With respect to Giardia, to date, there are only two studies that evaluate 
the performance of inhibitors on the life forms of the parasite. In one of 
these investigations8, antiretroviral protease inhibitors (Kaletra®, ritonavir 
and saquinavir) were assessed in vitro for their activity on trophozoite 
proliferation and the results revealed that Kaletra® was the most effective 
of them. More recently, in vitro and in vivo assays to evaluate the 
antigiardial potential of E-64 showed a significant inhibitory effect on 
parasite growth and on the efficiency of encystation11.
Fig. 1 - In vitro effect of E-64 inhibitor (µM) on the growth of G. duodenalis trophozoites, 
after incubation for 24, 48 and 72 hours. Non-treated cultures (NTC) and metronidazole-
treated cultures (MTZ) were included in all assays. Data expressed as means of trophozoites 
number (105) ± standard deviation (SD) in assays performed in triplicate.
Fig. 2 - In vitro effect of E-64 inhibitor (µM) on the adherence of G. duodenalis trophozoites, 
after incubation for 24 and 48 hours. Non-treated cultures (NTC) and metronidazole-treated 
cultures (MTZ) were included in all assays. Data expressed as means of attached trophozoites 
number (105) ± standard deviation (SD) in assays performed in triplicate.
Fig. 3 - Viability (MTT assay) of G. duodenalis after incubation with different concentrations 
of E-64 inhibitor (µM). Cultures treated with metronidazole (MTZ) at 40 µg/mL were 
included as control. The values correspond to mean ± standard deviation (SD) in assays 
performed in triplicate.
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Interestingly, E-64 was also able to inhibit trophozoite adherence and 
a marked detachment of 90% was observed in cultures exposed to the 
substance at 100 µM. It is important to emphasize that the attachment 
of Giardia trophozoites to intestinal mucosa is an essential factor for 
their colonization and survival in the host as well as for giardiasis 
pathogenesis. According to some authors, the adherence process has 
been considered as a potential target for chemotherapeutic alternatives 
that induce detachment and/or prevent the adhesion of parasite on the 
intestinal epithelium16. Another point to make is that substances that are 
capable of altering microtubule assembly of the trophozoites have the 
potential to affect a range of biological processes such as cytokinesis, 
locomotion, adhesion and detachment, situations that can enhance 
reduction in cell viability16.
Despite the E-64 in vitro effect, light microscope observations do 
not reveal marked alterations in trophozoites morphology. Although 
E-64 is a very useful cysteine inhibitor, it is known that its hydrophilic 
character is a property that can interfere in its cell permeability and 
impair the effective penetration through cell membranes25. In contrast to 
E-64, its synthetic analogues E-64c and E-64d act as potent membrane-
permeable cysteine protease inhibitors that can permeate an intact 
cell. Recently, in a study on the structure and function of the Giardia 
endomembrane system and the cysteine proteases, DUBOIS6 reported 
that growth was not affected by E-64d up to 50 µM. In addition, 
according to this author, the survival of trophozoites in the presence 
of this inhibitor did not differ from that observed in the untreated 
cultures. In view of these findings with E-64d and considering the 
observations in the present study when E-64 was able to reduce parasite 
growth by ≥ 50% at concentrations of 50 and 100 µM, future studies 
are a prerequisite to elucidate in more detail the effects of E-64 and its 
derivatives on Giardia biological processes.
The findings assembled herein lead us to suggest that E-64 can 
interfere in some crucial process in relation to the parasite survival, but 
until today little is known about the efficacy and safety of this protease 
inhibitor in vivo. So, it is suitable that the concentrations assessed in vitro 
must be tested in vivo before a definitive statement can be made on its 
antiparasitic potential. Even so, our results provide insights on protease 
inhibitors targeting parasite cysteine proteases open perspectives for 
future investigations in order to confirm the real antigiardial potential 
of E-64 and other potent inhibitors of cysteine proteases.
RESUMO
Atividade in vitro do inibidor de cisteína-proteases E-64 sobre 
trofozoítos de Giardia
As cisteína-proteases estão entre os alvos mais promissores para o 
desenvolvimento de novos agentes terapêuticos, visto que participam 
de eventos fundamentais do ciclo de vida de muitos microorganismos, 
inclusive Giardia. Como a atividade das proteases pode ser controlada 
por inibidores específicos, essas substâncias têm sido avaliadas quanto ao 
potencial antiparasitário. Diante disso, o presente estudo teve por objetivo 
avaliar o efeito in vitro do inibidor de cisteína-proteases E-64 sobre o 
crescimento, a aderência e a viabilidade de trofozoítos de cepa de Giardia 
isolada em Botucatu. Nos ensaios de crescimento e aderência, o número 
de trofozoítos foi estimado microscopicamente em hemocitômetro, 
enquanto que a viabilidade celular foi avaliada pelo método do MTT. No 
presente estudo, embora o metronidazol tenha se apresentado bastante 
efetivo, o E-64 mostrou ser capaz de inibir o crescimento, a aderência 
e a viabilidade em taxas superiores a 50%, especialmente nos cultivos 
expostos à concentração de 100 µM. A despeito de preliminares, esses 
resultados demonstram que o inibidor E-64 pode interferir em processos 
primordiais para a sobrevivência do parasita, além do que, abrem novas 
perspectivas para investigações futuras a fim de se avaliar o real potencial 
giardicida dos inibidores de proteases.
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